2aG4 / Avid Bioservices - LARVOL DELTA

Application prospects of the 2BS cell-adapted China fixed rabies virus vaccine strain 2aG4-B40. (PubMed, Virol J) - "In this study, a 2BS cell-adapted strain of the 2aG4 rabies virus was obtained by passage for 40 generations. The results of sequencing analysis and titre determination of the adapted strain showed that the mutations in the adaptive process are not located at key sequence regions of the virus, and these mutations may enhance the affinity of the adapted strain for human diploid cells. Moreover, vaccines made from the adapted strain 2aG4-B40 had high potency and immunogenicity and could be an ideal candidate rabies virus strain for inactivated vaccine preparation."

Journal • Infectious Disease

[VIRTUAL] Inhibiting Growth of Human Triple-Negative Breast Cancer Cells by Activating Mutant p53 Protein Alone or in Combination With a Phosphatidylserine-Targeting Antibody (ENDO 2021) - "A third group was given both APR-246 and 2aG4 using the same doses above. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO 2021."

Combination therapy • IO biomarker • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • BCL2 • CASP3 • CDKN1A • HER-2 • PGR • TP53

Drugging MYCN oncogenic signalling through the MYCN-PA2G4 binding interface. (PubMed, Cancer Res) - "Here, we reveal the oncogenic role of a novel MYCN target and binding protein, proliferation-associated 2AG4 (PA2G4)...Treated tumors showed reduced levels of both MYCN and PA2G4. Our findings demonstrate a critical role for PA2G4 as cofactor in MYCN-driven neuroblastoma and highlight competitive inhibition of the PA2G4-MYCN protein binding as a novel therapeutic strategy in the disease."

Journal • Neuroblastoma • Oncology • Solid Tumor • Targeted Protein Degradation

Activation of toll-like receptors via PS-targeting monoclonal antibodies (SITC 2019) - "Bavituximab and other PS-targeting mAbs (2aG4 and 1N11) bind to PS via beta-2 glycoprotein 1 (b2GP1). These studies demonstrate that the PS-targeting mAbs stimulate Spi-C expression in a b2GP1-dependent manner. Overall these data support that one mechanism of innate immune activation induced by PS-targeting mAbs is through TLR2 stimulation on myeloid cells. Future studies are focused on validating these results in vivo using Tlr-deficient and b2gp1-deficient mice."

IO Biomarker

APR-246 alone and in combination with a phosphatidylserine-targeting antibody inhibits lung metastasis of human triple-negative breast cancer cells in nude mice. (PubMed, Breast Cancer (Dove Med Press)) - "In this study, we sought to determine whether administration of APR-246, either alone or in combination with 2aG4, an antibody that targets phosphatidylserine residues on tumor blood vessels and disrupts tumor vasculature, effectively inhibits stem cell-like characteristics of tumor cells and migration in vitro, and metastasis of human mtp53-expressing TNBC cells to the lungs in mouse models. Metastasis of human mtp53-expressing TNBC cells to the lungs of nude mice is inhibited by the treatment that combines activation of mtp53 with targeting of phosphatidylserine residues on tumor blood vessels. We contend therefore that our findings strongly support the use of combination treatment involving mtp53 activation and immunotherapy in patients with TNBC."

Combination therapy • IO Biomarker • Journal • Preclinical

Targeting Mutant p53 Alone or in Combination with a Phosphatidylserine Specific Antibody Suppresses Growth and Metastasis of Human Breast Cancer: A Strategy Towards Enhancing Personalized Medicine (ENDO 2019) - "The aim of this study was to determine whether administration of APR-246, a small molecule that restores p53 function, either alone or in combination with 2aG4, an antibody that disrupts tumor blood vessels by targeting phosphatidylserine (high levels of which are present in tumor blood vessels) effectively suppresses breast cancer growth and metastasis. Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO."

Combination therapy • Late-breaking abstract